ArticleNeuroscience bulletin2026
Optimized Midbrain Organoid Transplantation Restores Dopaminergic Nigrostriatal Pathway and Motor Function in Parkinson's Disease Mouse Model.
Article in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is characterized by the progressive degeneration of midbrain dopaminergic (DA) neurons, leading to disruption of the nigrostriatal pathway and motor deficits. Here, we present an optimized protocol for generating human midbrain organoids (hMOs) suitable for homotopic transplantation, through sequential modifications. Homotopic transplantation of these optimized hMOs into the substantia nigra (SN) of 6-hydroxydopamine (6-OHDA)-lesioned PD mice resulted in significant graft survival, with a majority of grafted cells expressing the A9-specific neuronal marker GIRK2. The grafts reconstituted the nigrostriatal pathway, as confirmed by restored DA fiber density, elevated striatal dopamine levels, and retrograde AAV tracing. These structural improvements were accompanied by notable behavioral recovery, including reduced apomorphine-induced rotations, enhanced rotarod performance, and restored limb symmetry in cylinder tests. Our findings demonstrate that optimized hMOs, when transplanted into their native niche, can reestablish functional circuitry and alleviate motor deficits, providing an efficient and clinically relevant strategy for PD therapy.
Indexed as
Identifiers
42406285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.